CIM
KROS icon

Cambria Investment Management’s Keros Therapeutics KROS Stock Holding History

Cambria Investment Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-31,312
Closed -$638K – 692
2025
Q4 		$638K Buy
+31,312
New +$549K 0.04% 336

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Cambria Investment Management's KROS Position: Q1 2026 in Review

Cambria Investment Management sold out of Keros Therapeutics (KROS) in Q1 2026, closing a stake of 31,312 shares — an estimated $638K sold.

Cambria Investment Management first reported a position in KROS in Q4 2025 and held it in 1 quarter. The position peaked at $638K in Q4 2025. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

  • Cambria Investment Management reported no remaining Keros Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Cambria Investment Management sold 31,312 Keros Therapeutics shares in Q1 2026, an estimated $638K.
  • Cambria Investment Management first reported a position in Keros Therapeutics in Q4 2025 and held it in 1 quarter.
  • Cambria Investment Management's Keros Therapeutics position peaked at $638K in Q4 2025.
  • 151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on Cambria Investment Management's 13F filing for Q1 2026, filed 15 May 2026.